Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Genenta Science SPA GNTA

Healthcare Biotechnology
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:GNTA)

Genenta Science Provides Update on CEO Ownership

GlobeNewswire December 19, 2025

Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial

GlobeNewswire November 24, 2025

Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares

GlobeNewswire October 26, 2025

Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production

GlobeNewswire October 24, 2025

Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals

GlobeNewswire July 1, 2025

Genenta Science, SpA Announces Participation in the D. Boral Capital Inaugural Global Conference

Newsfile May 8, 2025

Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies

GlobeNewswire May 7, 2025

Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar

GlobeNewswire April 15, 2025

Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates

GlobeNewswire March 19, 2025
View More News ››

Opinion & Analysis (NDAQ:GNTA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:GNTA)

Sell buddy sell.

Otherwise LOSO for shareholders today anyway
coolfooldumbguy - October 27, 2025

Buy buddy buy.

Otherwise it will be FOMO time for you fellas out there today anyway,so good luck to all 
coolfooldumbguy - October 24, 2025
View more Bullboard ››

Sranan Gold Corp.

Sranan Gold Corp.

Sranan Gold Corp. develops, acquires, and explores mineral properties in Canada. The company primarily explores gold deposits ...
View More »

Podcasts